原发脑肿瘤中平足蛋白表达诱导血小板聚集并增加静脉血栓栓塞风险
在维也纳癌症与血栓形成研究(前瞻性观察队列)的213例原发脑肿瘤患者(89%为高级别胶质瘤)中,151例肿瘤标本平足蛋白染色阳性;2年随访29例(13.6%)发生静脉血栓栓塞。高表达平足蛋白者静脉血栓栓塞风险增加(高表达 vs 无表达 HR 5.71,95%CI 1.52-21.26,P=010),体外实验显示平足蛋白阳性胶质母细胞瘤细胞诱导血小板聚集,抗平足蛋白抗体可阻断该聚集。
要点
- 213例原发脑肿瘤患者中151例肿瘤标本平足蛋白染色阳性,2年随访29例(13.6%)发生静脉血栓栓塞。
- 高平足蛋白表达与静脉血栓栓塞风险增加相关(高表达 vs 无表达 HR 5.71,95%CI 1.52-21.26,P=010)。
- 平足蛋白阳性原发胶质母细胞瘤细胞体外诱导人血小板聚集,抗平足蛋白抗体可阻断该聚集。
核心结论
- 原发脑肿瘤中高平足蛋白表达诱导血小板聚集,与高凝状态相关,并与静脉血栓栓塞风险增加相关。
- 数据为原发脑肿瘤中静脉血栓栓塞的发病机制提供了新见解。
研究设计与样本
- 研究纳入维也纳癌症与血栓形成研究(前瞻性观察队列,对象为新诊断癌症或疾病进展患者,旨在识别静脉血栓栓塞风险患者)中213例原发脑肿瘤患者的肿瘤标本,其中高级别胶质瘤占89%。
- 对肿瘤标本进行平足蛋白和瘤内血小板聚集物的免疫组化染色,并体外研究原代人胶质母细胞瘤细胞诱导的血小板聚集。
主要发现
- 2年随访期间29例(13.6%)患者发生静脉血栓栓塞。
- 151例肿瘤标本平足蛋白染色阳性(高表达33例、中表达47例、低表达71例)。
- 平足蛋白阳性肿瘤患者外周血小板计数更低(P < .001)、D-二聚体水平更高(P < .001)。
- 平足蛋白染色强度与肿瘤标本中血管内血小板聚集物水平升高相关(P < .001)。
- 高平足蛋白表达与静脉血栓栓塞风险增加相关(高表达 vs 无表达的风险比 5.71;95%置信区间 1.52-21.26;P =010),独立于年龄、性别和肿瘤类型。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is common in patients with brain tumors, and underlying mechanisms are unclear. We hypothesized that podoplanin, a sialomucin-like glycoprotein, increases the risk of VTE in primary brain tumors via its ability to induce platelet aggregation. Immunohistochemical staining against podoplanin and intratumoral platelet aggregates was performed in brain tumor specimens of 213 patients (mostly high-grade gliomas [89%]) included in the Vienna Cancer and Thrombosis Study, a prospective observational cohort study of patients with newly diagnosed cancer or progressive disease aimed at identifying patients at risk of VTE. Platelet aggregation in response to primary human glioblastoma cells was investigated in vitro. During 2-year follow-up, 29 (13.6%) patients developed VTE. One-hundred fifty-one tumor specimens stained positive for podoplanin (33 high expression, 47 medium expression, 71 low expression). Patients with podoplanin-positive tumors had lower peripheral blood platelet counts (P < .001) and higher D-dimer levels (P < .001). Podoplanin staining intensity was associated with increasing levels of intravascular platelet aggregates in tumor specimens (P < .001). High podoplanin expression was associated with an increased risk of VTE (hazard ratio for high vs no podoplanin expression: 5.71; 95% confidence interval, 1.52-21.26; P =010), independent of age, sex, and tumor type. Podoplanin-positive primary glioblastoma cells induced aggregation of human platelets in vitro, which could be abrogated by an antipodoplanin antibody. In conclusion, high podoplanin expression in primary brain tumors induces platelet aggregation, correlates with hypercoagulability, and is associated with increased risk of VTE. Our data indicate novel insights into the pathogenesis of VTE in primary brain tumors.
引用
- Riedl J, Preusser M, Nazari PM, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017. PMID: 28073783. doi:10.1182/blood-2016-06-720714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。